A clinical comparison of phenelzine and electro-convulsive therapy in the treatment of depressive illness
- 1 September 1962
- journal article
- Published by Royal College of Psychiatrists in Journal of Mental Science
- Vol. 108 (456) , 708-710
- https://doi.org/10.1192/bjp.108.456.708
Abstract
The mono-amine oxidase inhibitors, of which phenelzine (“Nardil”) is one example, were introduced for the treatment of depressive illness as a result of the observation that iproniazid, which is a mono-amine oxidase inhibitor, produced euphoria and increased mental alertness in some tuberculous patients to whom it was given. Trials of iproniazid in mental illness were carried out (Loomeret al., 1957; Cesarman, 1959), but it was found to be very liable to give rise to side-effects, being particularly toxic to the liver. Other less toxic mono-amine oxidase inhibitors such as phenelzine, which is chemically related to iproniazid, were later developed.Keywords
This publication has 3 references indexed in Scilit:
- IPRONIAZID IN CARDIOVASCULAR THERAPY, WITH SPECIAL REFERENCE TO ITS ACTION IN ANGINA PECTORIS AND BLOOD PRESSUREAnnals of the New York Academy of Sciences, 1959
- The Assessment of Some Symptoms and Signs of Depression in WomenJournal of Mental Science, 1959
- Face validity in the D scale of the MMPIJournal of Clinical Psychology, 1958